Yee EJ, Gilbert D, Kaplan J, van Dyk L, Kim SS, Berg L, Clambey E, Wani S, McCarter MD, Stewart CL. Immune Landscape of Epstein-Barr Virus-Associated Gastric Cancer: Analysis From a Western Academic Institution. J Surg Res. 2024 Feb 17;296:742-750. [Epub ahead of print] PubMed PMID: 38368775
Yee EJ, Gilbert D, Kaplan J, Wani S, Kim SS, McCarter MD, Stewart CL. Effect of Neoadjuvant Chemotherapy on Tumor-Infiltrating Lymphocytes in Resectable Gastric Cancer: Analysis from a Western Academic Center. Cancers (Basel). 2024 Apr 7;16(7). PubMed PMID: 38611107
Balmaceda NB, Petrillo A, Krishnan M, Zhao JJ, Kim S, Klute KA, Sundar R. State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e431060. PubMed PMID: 38771996
Shitara K, Shah MA, Lordick F, Bang YJ, Ilson D, Cutsem EV, Enzinger P, Kim SS, Klempner SJ, Moran D, Park JW, Bhattacharya P, Ajani JA, Xu RH. Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary. Future Oncol. 2024 May 24;:1-17. [Epub ahead of print] PubMed PMID: 38861294
Catenacci DV, Kang YK, Uronis HE, Lee KW, Ng MC, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Oh DY, Yen J, Odegaard JI, Lagow E, Li D, Sun J, Kaminker P, Moore PA, Rosales MK, Park H. Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. Oncology (Williston Park). 2023 Apr 25;37(4):176-183. PubMed PMID: 37104758
Pandey A, Lieu CH, Kim SS. The Local Microbiome in Esophageal Cancer and Treatment Response: A Review of Emerging Data and Future Directions. Cancers (Basel). 2023 Jul 10;15(14). PubMed PMID: 37509225
Schreiber AR, Kagihara JA, Corr BR, Davis SL, Lieu C, Kim SS, Jimeno A, Camidge DR, Williams J, Heim AM, Martin A, DeMattei JA, Holay N, Triplett TA, Eckhardt SG, Litwiler K, Winkler J, Piscopio AD, Diamond JR. First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors. Cancers (Basel). 2023 Dec 23;16(1). PubMed PMID: 38201519
Balmaceda NB, Kim SS. Immunotherapy in Esophagogastric Cancer: Treatment Landscape, Challenges, and New Directions. J Gastrointest Cancer. 2023 Dec 21. [Epub ahead of print] PubMed PMID: 38127239
Kim S. The role of antiangiogenesis agents in refractory metastatic colorectal cancer. Clin Adv Hematol Oncol. 2023 Apr;21(4):209-212. PubMed PMID: 37039731
Cerniglia M, Klepadlo M, Sheneman D, Kim SS. Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC. BMJ Case Rep. 2022 Aug 12;15(8). PubMed PMID: 35961684
Redman JM, Tsai YT, Weinberg BA, Donahue RN, Gandhy S, Gatti-Mays ME, Abdul Sater H, Bilusic M, Cordes LM, Steinberg SM, Marte JL, Jochems C, Kim SS, Marshall JL, McMahon S, Redmond E, Schlom J, Gulley JL, Strauss J. A Randomized Phase II Trial of mFOLFOX6 Bevacizumab Alone or with AdCEA Vaccine Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. Oncologist. 2022 Mar 11;27(3):198-209. PubMed PMID: 35274710
Cerniglia M, Xiu J, Grothey A, Pishvaian MJ, Baca Y, Hwang JJ, Marshall JL, VanderWalde AM, Shields AF, Lenz HJ, Korn WM, Salem M, Philip PA, Goldberg RM, Zeng J, Kim SS. Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. Mol Cancer Ther. 2022 Jan;21(1):227-236. PubMed PMID: 34725190
Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Feb;20(2):167-192. PubMed PMID: 35130500
Ho F, Torphy RJ, Friedman C, Leong S, Kim S, Wani S, Schefter T, Scott CD, Mitchell JD, Weyant MJ, Meguid RA, Gleisner AL, Goodman KA, McCarter MD. Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma. Ann Surg Oncol. 2021 Nov;28(12):7208-7218. PubMed PMID: 33884489
Pedersen KS, Foster NR, Overman MJ, Boland PM, Kim SS, Arrambide KA, Jaszewski BL, Bekaii-Saab T, Graham RP, Welch J, Wilson RH, McWilliams RR. ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. Clin Cancer Res. 2021 Jul 1;27(13):3641-3648. PubMed PMID: 33883178
Burke AM, Yeh C, Kim S, Bergquist P, Krishnan P, Barac A, Srichai MB, Unger K. A Prospective Study of Early Radiation Associated Cardiac Toxicity Following Neoadjuvant Chemoradiation for Distal Esophageal Cancer. Front Oncol. 2020;10:1169. PubMed PMID: 32903617
Pishvaian MJ, Wang H, He AR, Hwang JJ, Smaglo BG, Kim SS, Weinberg BA, Weiner LM, Marshall JL, Brody JR. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clin Cancer Res. 2020 Oct 1;26(19):5092-5101. PubMed PMID: 32669374
Catenacci DVT, Kang YK, Park H, Uronis HE, Lee KW, Ng MCH, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Bendell JC, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Lockhart AC, Knutson KL, Yen J, Franovic A, Nordstrom JL, Li D, Wigginton J, Davidson-Moncada JK, Rosales MK, Bang YJ. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. Lancet Oncol. 2020 Aug;21(8):1066-1076. PubMed PMID: 32653053
Villano AM, Zeymo A, McDermott J, Crocker A, Zeck J, Chan KS, Shara N, Kim S, Al-Refaie WB. Evaluating Dissemination of Adequate Lymphadenectomy for Gastric Cancer in the USA. J Gastrointest Surg. 2019 Nov;23(11):2119-2128. PubMed PMID: 30788715
Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States. Adv Ther. 2018 Oct;35(10):1564-1577. PubMed PMID: 30209750
Choe HK, De Sancho MT, Kim SS, Dai T, Shah MA. Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies. Blood Coagul Fibrinolysis. 2018 Mar;29(2):227-230. PubMed PMID: 29389673
Kim S, Abou-Alfa GK. The role of tyrosine kinase inhibitors in hepatocellular carcinoma. Clin Adv Hematol Oncol. 2014 Jan;12(1):36-41. PubMed PMID: 25000314
Wan DW, Tzimas D, Smith JA, Kim S, Araujo J, David R, Lobach I, Sarpel U. Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States. Am J Gastroenterol. 2011 Nov;106(11):1994-2000. PubMed PMID: 21912436
Cancers - Gastroenterologic Cancer (Colon, Stomach, Esophageal, Liver)
Cancers - Pancreatic Cancer
Clinical Interests
Gastrointestinal Medical Oncology
Care Philosophy
I strive to provide patients with individualized care after careful and thoughtful discussion. I strongly believe that my job is to present all options to patients so that we can make the best possible treatment decisions, together.
To that end, I am dedicated to contributing to the field by leading research to advance our understanding of gastrointestinal cancers to uncover more effective treatment options. I serve as the Principal Investigator on multiple investigator initiated and industry sponsored clinical trials. I also sit on several national committees including
National Comprehensive Cancer Network (NCCN) Gastric and Esophageal Cancers Guidelines and American Society of Clinical Oncology (ASCO) Evidence Based Medicine Committee.
General Information
Medical Schools:
MD, Columbia University College of Physicians and Surgeons
(2009)
Undergraduate Schools:
BA, Columbia University (NY)
(2002)
Residency Programs:
New York University School of Medicine Program, Internal Medicine (2012)
Fellowships:
New York Presbyterian Hospital (Cornell Campus) Program, Hematology and Oncology
(2016)